- Home
- VNDA vs CRBU Comparison
VNDA vs CRBU Comparison
Compare VNDA & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNDA
- CRBU
- Stock Information
- Founded
- VNDA 2002
- CRBU 2011
- Country
- VNDA United States
- CRBU United States
- Employees
- VNDA N/A
- CRBU N/A
- Industry
- VNDA Biotechnology: Pharmaceutical Preparations
- CRBU Medicinal Chemicals and Botanical Products
- Sector
- VNDA Health Care
- CRBU Health Care
- Exchange
- VNDA Nasdaq
- CRBU Nasdaq
- Market Cap
- VNDA 270.0M
- CRBU 236.3M
- IPO Year
- VNDA 2006
- CRBU 2021
- Fundamental
- Price
- VNDA $4.77
- CRBU $1.79
- Analyst Decision
- VNDA Strong Buy
- CRBU Strong Buy
- Analyst Count
- VNDA 2
- CRBU 4
- Target Price
- VNDA $15.50
- CRBU $12.00
- AVG Volume (30 Days)
- VNDA 704.2K
- CRBU 1.5M
- Earning Date
- VNDA 02-05-2025
- CRBU 11-06-2024
- Dividend Yield
- VNDA N/A
- CRBU N/A
- EPS Growth
- VNDA N/A
- CRBU N/A
- EPS
- VNDA N/A
- CRBU N/A
- Revenue
- VNDA $190,858,000.00
- CRBU $11,475,000.00
- Revenue This Year
- VNDA $5.60
- CRBU N/A
- Revenue Next Year
- VNDA $42.85
- CRBU N/A
- P/E Ratio
- VNDA N/A
- CRBU N/A
- Revenue Growth
- VNDA N/A
- CRBU N/A
- 52 Week Low
- VNDA $3.46
- CRBU $1.50
- 52 Week High
- VNDA $6.75
- CRBU $8.33
- Technical
- Relative Strength Index (RSI)
- VNDA 42.69
- CRBU 37.96
- Support Level
- VNDA $4.49
- CRBU $1.72
- Resistance Level
- VNDA $4.81
- CRBU $1.97
- Average True Range (ATR)
- VNDA 0.18
- CRBU 0.14
- MACD
- VNDA -0.03
- CRBU -0.03
- Stochastic Oscillator
- VNDA 25.71
- CRBU 9.12
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.